Abivax Highlights Comprehensive Obefazimod Data at Upcoming Digestive Disease Week Conference
Presentations Feature New Phase 3 Data, Patient-Reported Outcomes, and Anti-Fibrotic Results
Abivax SA (NASDAQ:ABVX; PARIS:FR), a clinical-stage biotech focused on chronic inflammatory diseases, is set to unveil nine scientific abstracts detailing its lead therapy obefazimod during Digestive Disease Week (DDW), held May 2-5, 2026, in Chicago. These presentations home in on new efficacy, safety, and patient-reported outcomes from ongoing Phase 3 trials, along with promising preclinical anti-fibrotic activity for patients with ulcerative colitis (UC).
Phase 3 Data Underscore Efficacy and Safety Across Multiple Patient Groups
The company’s DDW lineup spotlights results from the ABTECT-1 and ABTECT-2 induction trials for moderately to severely active UC. Data to be presented will address:
- Histologic and combined histologic-endoscopic outcomes
- Early symptomatic improvement and fatigue reduction
- Efficacy in elderly and hard-to-treat patient subgroups
- Safety assessment pooled from both key trials
| Date & Time | Session | Abstract # | Title Highlights | Presenter |
|---|---|---|---|---|
| Mon, May 4 10:00-10:15 |
Controlled Clinical Trials 1 | 4470489 | Impact on histologic and endoscopic outcomes in Phase 3 trials | Prof. Fernando Magro, MD, PhD |
| Mon, May 4 12:30-1:30 |
Controlled Clinical Trials of IBD Treatment | Mo1513 | Early symptomatic improvement: pooled ABTECT-1/2 results | Prof. Marla Dubinsky, MD |
| Mon, May 4 12:30-1:30 |
Controlled Clinical Trials of IBD Treatment | Mo1533 | Efficacy & safety in elderly UC patients | Andres J Yarur, MD |
| Mon, May 4 12:30-1:30 |
Controlled Clinical Trials of IBD Treatment | Mo1522 | Results in prior inadequate responders to advanced therapy | Prof. Bruce E Sands, MD, MS |
| Mon, May 4 12:30-1:30 |
Quality of Life and Psychosocial Outcomes | Mo1677 | Improvements in patient-reported fatigue | Prof. Marla Dubinsky, MD |
| Tue, May 5 12:30-1:30 |
Mechanisms of IBD Therapeutics | Tu1433 | Dual anti-inflammatory and anti-fibrotic activity: preclinical data | Prof. Silvio Danese, MD, PhD |
| Tue, May 5 12:30-1:30 |
Mechanisms of IBD Therapeutics | Tu1449 | Obefazimod’s effect on mir-124 and key inflammatory cytokines | Parambir S Dulai, MD |
Patient-Focused Outcomes and Mechanistic Insights Lead the Agenda
Of particular note are presentations on patient-reported outcomes, such as improvements in fatigue and quality of life, pooled from both ABTECT-1 and ABTECT-2. Mechanistic studies will detail how obefazimod enhances miR-124 expression and lowers pro-inflammatory cytokines such as IL-17A and IL-6. Early data on anti-fibrotic activity further distinguish obefazimod in the crowded field of UC therapies, with dual effects demonstrated in both human and animal models.
Management Confident in Broad Potential for Obefazimod
Fabio Cataldi, MD, the company’s Chief Medical Officer, highlighted the depth of efficacy and quality-of-life findings: "These abstracts paint a comprehensive picture of a therapy with potential to address what matters most to patients and clinicians alike." CEO Marc de Garidel echoed this confidence, emphasizing that the emerging dataset on obefazimod supports Abivax's drive to bring innovation in inflammatory bowel disease to the clinic.
Key Takeaway: Multiple Data Streams Bolster Obefazimod’s Differentiation
With a robust mix of clinical and preclinical results to be shared at DDW, Abivax is clearly positioning obefazimod as a potential new standard for patients with moderately to severely active UC. Investors and clinicians alike will want to monitor outcomes from these presentations, as they could shape expectations for future regulatory filings and commercial strategy.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI